Boryeong Pregabalin Capsule 150 mg
Pregabalin 150mg
Prescription medication
Boryeong Co., Ltd.
MFDS item code 202001636 · Approved 2020.03.10
This product's status changed to Expired on 2025.03.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures in epilepsy; treatment of fibromyalgia
This medication is used to relieve peripheral and central neuropathic pain in adults. It is also suitable as an adjunctive therapy to control partial seizures in patients with epilepsy. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, this medication is effective in improving symptoms associated with various nerve-related disorders.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’.) 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with renal impairment should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered once. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with renal impairment.
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 to 17 years: Administration is not recommended.
This medication is used as an anticonvulsant, and there is an increased risk of developing mental health issues such as suicidal thoughts or behavior, and depression during treatment. Therefore, patients taking this medication should immediately inform their healthcare provider of any changes in mood or behavior. This medication should not be administered to patients with hypersensitivity to its ingredients or those with certain genetic lactose intolerance. Diabetic patients may experience weight gain from this medication, which may require adjustment of their blood sugar control medications. Allergic reactions such as angioedema may occur, so if swelling of the face or around the mouth occurs, medication should be discontinued immediately. Elderly patients may experience increased dizziness or drowsiness when taking this medication and should be cautious about falling; neurological symptoms such as loss of consciousness or confusion may also be observed. Visual disturbances such as blurred vision may occur, and these symptoms may improve after discontinuation of the medication. There is insufficient information on the cessation of other anticonvulsants before using this medication alone, and caution is advised. Abrupt withdrawal may result in withdrawal symptoms such as insomnia, headaches, nausea, and anxiety, so gradual reduction as per doctor's instructions is necessary. Patients with a history of substance abuse should be closely monitored due to a higher risk of misuse of this medication. Patients with decreased renal function may require dose adjustments, and there have been cases where renal function improved after discontinuing or reducing the dose of this medication. Careful administration is needed for patients with heart disease, especially those with congestive heart failure. Combining this medication with other drugs that have central nervous system depressant effects may increase the risk of respiratory depression, thus caution is required. While taking this medication, caution should be observed when driving or operating hazardous machinery, as dizziness or drowsiness may occur. In early pregnancy, there may be a risk of congenital malformations to the fetus; thus, women who are pregnant or planning to become pregnant should consult a healthcare provider before taking this medication and use effective contraception. Lactating women should decide carefully whether to discontinue breastfeeding or the medication, as this drug may pass into breast milk and affect the baby. In cases of overdose, symptoms may include drowsiness, confusion, depression, and seizures; professional treatment, including possible dialysis, may be required. This medication should be stored in a safe place out of reach of children, and it should not be transferred to other containers. Various side effects may occur with this medication, so it is important to consult a healthcare provider immediately if any unusual symptoms appear.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. The storage temperature should be between 15 and 30 degrees Celsius, avoiding excessively hot or cold places.
A hard capsule of white color with white or light yellow powder inside.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Prescription medication
Boryeong Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.